According to filings with the U.S. Securities and Exchange Commission, Spiral Therapeutics has raised $27,000,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Spiral Therapeutics
Spiral Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for inner ear disorders, including hearing loss and balance disorders. Spiral’s MICS (Minimally-Invasive Cochlear System) drug delivery platform is designed to enable minimally invasive, precise and durable exposure of therapeutics to the cochlea. The company is advancing a pipeline of programs intended to address significant unmet needs across inner ear diseases.

To learn more, visit https://www.spiraltx.com/
LinkedIn: https://www.linkedin.com/company/spiral-therapeutics/

Contact:
Hugo Peris, Chief Executive Officer
https://www.linkedin.com/in/hugoperis/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.